Firm got about $1.38 million to conduct IND-enabling studies on small molecule.

Charlesson received two SBIR grants from the NIH totaling close to $1.6 million to support development of a nanoparticle-formulated therapy for eye disease and a preclinical genetic animal model for age-related macular degeneration (AMD).

Specifically, the firm obtained $210,357 to validate and commercialize its mouse model of AMD. Charlesson also received  over $1.38 million in a phase 2 SBIR grant to develop CLT-004 for treating AMD, diabetic retinopathy, and diabetic macular edema. These funds will be used to develop IND-enabling efficacy, safety, and toxicity profiles.

CLT-004 is a small molecule that reduces retinal inflammation and vascular leakage, according to Charlesson. The firm is developing a sustained-release nanoparticle formulation of CLT-004 to treat blinding retinal disease.

Previous articleResearchers Find How Tregs Suppress Antitumor Immune Responses Despite Reduced Functionality
Next articleBlood Stem Cell and Neuron Fusion Occurs More Frequently in Chronic Inflammation